Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab

Abstract

French

Background

Rituximab (RTX) is increasingly used for the treatment of pemphigus and pemphigoid disorders. The high cost of RTX frequently limits its use and access.

Objective

To determine the health system resources and costs associated with RTX treatment of pemphigus and pemphigoid.

Methods

Health system resources and costs attributed to a convenience sample of 89 patients with either pemphigus or pemphigoid were identified, quantified, and valued 6 months prior to and following RTX initiation between May 2006 and August 2012. Overall cohort costs and costs per patient were calculated (2013 Can$).

Results

The overall cohort cost for 6 months pre-RTX was $3.8 million and for 6 months post-RTX was $2.6 million. The average cost per patient decreased from $42,231 to $29,423 (30.3% decrease). The main cost driver was intravenous immunoglobulin.

Conclusions

Our findings suggest that RTX is effective in reducing health system resources and the costs associated with the treatment of pemphigus and pemphigoid.

Get full access to this article

View all access options for this article.

References

Joly

, Litrowski

Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis).

Clin Dermatol 2011; 29: 432–6, doi:10.1016/j.clindermatol.2011.01.013.

Kasperkiewicz

, Zillikens

, Schmidt

Pemphigoid diseases: pathogenesis, diagnosis, and treatment.

Autoimmunity 2012; 45: 55–70, doi:10.3109/08916934.2011.606447.

Bystryn

, Steinman

NM.

The adjuvant therapy of pemphigus. An update.

Arch Dermatol 1996; 132: 203–12, doi:10.1001/archderm.1996.03890260105016.

Zakka

, Shetty

, Ahmed

AR.

Rituximab in the treatment of pemphigus vulgaris.

Dermatol Ther (Heidelb) 2012; 2: 17, doi:10.1007/s13555-012-0017-3.

Gurcan

, Keskin

, Stem

JN.

A review of the current use of rituximab in autoimmune diseases.

Int Immunopharmacol 2009; 9: 10–25, doi:10.1016/j.intimp.2008.10.004.

Baum

, Gilboa

, Greenberger

Adjuvant rituximab therapy in pemphigus: a single-center experience of 18 cases.

J Dermatolog Treat 2013; 24: 427–30, [Epub 2013 May 21], doi:10.3109/09546634.2013.784391

Bank of Canada. Inflation calculator. 2013. Available at: http://www.bankofcanada.ca/rates/related/inflation-calculator/ (accessed June 6, 2013).

Ontario Ministry of Health and Longterm Care. Formulary search. Available at: https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp (accessed May 10, 2013).

McKesson

Medis price catalogue. 2013. Available at: http://www.mckesson.com/about-mckesson/our-company/businesses/mckesson-medical-surgical/medical-supplies-and-equipment/.

10.

Mittmann

, Verma

, Koo

Cost effectiveness of TAC versus FAC in adjuvant treatment of node-positive breast cancer.

Curr Oncol 2010; 17: 7–16.

11.

Canadian Institute for Health Information. Hospital cost drivers technical report: what factors have determined hospital expenditure trends in Canada. Available at: http://www.cihi.ca/CIHI-ext-portal/pdf/internet/HOSPITAL_COSTDRIVER_TECH_EN (accessed May 13, 2013).

12.

Ontario Community Support Association. Unleashing attendant services: enhancing people's potential, reducing wait times in acute and longterm care. 2008. Available at: http://www.homecareontario.ca/public/docs/publications/OCSA-Attendant-Services-Report-2008.pdf (accessed May 13, 2013).

13.

Working in Canada. Careers by wages and outlook. Available at: http://www.workingincanada.gc.ca/wage-outlook_search-eng.do?reportOption=wage (accessed May 15, 2013).

14.

Ontario Ministry of Health and Longterm Care. Schedule of benefits for physician services under the Health Insurance Act. Available at: http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv_mn.html (accessed May 13, 2013).

15.

City of Toronto. Communicable disease control: tuberculosis. Available at: http://www.toronto.ca/health/tb_prevention/igra_testing.htm (accessed May 13, 2013).

16.

Ontario Ministry of Health and Longterm Care. Ontario Health Insurance (OHIP) schedule of benefits and fees: schedule of benefits for laboratory services. Available at: http://www.health.gov.on.ca/english/providers/program/ohip/sob/lab/lab_mn.html (accessed May 14, 2013).

17.

Leventhal

, Sanchez

MR.

Is it time to re-evaluate the treatment of pemphigus?

J Drugs Dermatol 2012; 11: 1200–6.

18.

Daoud

, Amin

KG.

Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.

Int Immunopharmacol 2006; 6: 600–6, doi:10.1016/j.intimp.2005.11.002.

19.

Daoud

, Amin

, Mohan

, Ahmed

AR.

Cost of intravenous immunoglobulin therapy versus conventional immunosuppressive therapy in patients with mucous membrane pemphigoid: a preliminary study.

Ann Pharmacother 2005; 39: 2003–8, doi:10.1345/aph.1E595.

20.

Johnston

, Bolbocean

, Connors

, Peacock

Cost-effectiveness of rituximab in follicular lymphoma.

Expert Rev Pharmacoecon Outcomes Res 2012; 12: 569–77, doi:10.1586/erp.12.57.

21.

Launois

, Payet

, Saidenberg-Kermanac'h

Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis.

Joint Bone Spine 2008; 75: 688–95, doi:10.1016/j.jbspin.2008.04.012.

22.

Papaioannou

, Rafia

, Rathbone

Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.

Health Technol Assess 2012; 16: 1–253, iii-iv.

23.

Hallinen

, Soini

, Eklund

, Puolakka

Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.

Rheumatology (Oxford) 2010; 49: 767–77, doi:10.1093/rheumatology/kep425.